An Australian company that manufactures radioactive drugs that help treat and diagnose diseases will acquire a German isotope maker in a transaction worth up to $3.3 billion.
ASX-listed Telix Pharmaceuticals will pay at least $US1.65 billion ($2.3 billion) in scrip upfront for ITM Isotope Technologies Munich, a private radioisotope manufacturer with a global distribution network that spans more than 65 countries.